Navigation Links
Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
Date:2/13/2013

NORTHBROOK, Ill., Feb. 13, 2013 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that more than 10 abstracts from Astellas oncology pipeline agents and marketed products will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), to be held February 14-16 in Orlando, Florida.

"We're committed to delivering new treatment options for patients with GU cancers," said Mark Reisenauer , vice president, Astellas Oncology. "The data to be presented at ASCO GU further illustrates the potential role our products can play."

Key presentations to be made at ASCO-GU include:

Enzalutamide

Data from a 25-week, open label, single-arm phase 2 study highlighting the effect of enzalutamide on prostate-specific antigen (PSA) response in men with hormone-naive prostate cancer will be presented. Five additional abstracts will highlight outcomes from a phase 1 study of enzalutamide in combination with docetaxel chemotherapy, as well as additional findings from the randomized, global, placebo-controlled phase 3 AFFIRM study of enzalutamide in men with metastatic castration resistant prostate cancer. XTANDI was approved by the FDA on August 31, 2012 for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (chemotherapy). A Marketing Authorization Application for XTANDI is currently under review by the European Medicines Agency (EMA).

Tivozanib

Additional secondary analysis results from the Phase 3 TIVO-1 (tivozanib versus sorafenib in 1st line advanced RCC) trial will be presented.  Reported data will include overall survival (OS) results for metastatic renal cell carcinoma (mRCC) patients who received ti
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
2. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
3. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
4. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
5. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
6. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
7. CTIA-The Wireless Association Highlights Connected Health Benefits and Potential
8. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
9. Philips Highlights Future Innovations at RSNA 2012 Transformation Lab
10. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
11. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
(Date:12/15/2014)... 15, 2014 BerGenBio AS, a ... drug resistant cancers, today announces that it has raised ... from new and existing investors. BerGenBio will ... development of its pipeline of innovative cancer therapeutics, in ... drug candidate, BGB324, a first-in-class selective Axl kinase inhibitor, ...
(Date:12/15/2014)... -- Colorado and Washington State are not ... Oregon , Alaska , ... the November 2014 elections. Photo - ... The benefits of legalizing cannabis are manifold. There ... increased tax revenue for state and local governments, in addition ...
Breaking Medicine Technology:MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2BerGenBio Completes NOK90 Million Fundraising 2CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2
... Aug. 13 BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: ... marketing and distribution partner in Japan, has,submitted a ... Japanese Ministry of Health, Labour and Welfare. ... to bring the first drug,treatment option to MPS ...
... Texas, Aug. 13 Lexicon,Pharmaceuticals, Inc. (Nasdaq: ... an oral presentation at the American Chemical Society ... August 21, 2007,at 2:50 p.m. Eastern Time. The ... serotonin levels by enzyme inhibitors for the,potential treatment ...
Cached Medicine Technology:BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health 2BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health 3BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health 4Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 2Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate 3
(Date:12/17/2014)... Expectant parents should leave prenatal picture-taking to medical professionals, ... of ultrasound imaging and heartbeat monitors to get "keepsake" ... warns. "Although there is a lack of ... heartbeat monitors, prudent use of these devices by trained ... biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... improve overall health, but a growing body of evidence shows ... review finds. In fact, the benefits were similar to ... researcher Paula Chu, a doctoral candidate at Harvard University,s Health ... trials, found that people randomly assigned to take yoga classes ...
(Date:12/15/2014)... December 15, 2014 Veretekk.com, Inc. announced ... Ocean Avenue. JM Ocean Avenue has secured exclusive ... online automated marketing system. JM Ocean Avenue is ... merger of Ocean Avenue and JM International, with partial ... Billion per year company. , “After nearly 2 decades ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... Minn. Mayo Clinic has received investigational ... the Food and Drug Administration ( http://www.fda.gov/ ... mobilize the body,s defense mechanisms to destroy ... first aimed at preventing cancer recurrence. The ...
... News) -- Although not life-threatening, sprains and strains account ... in U.S. emergency departments, according to a new study. ... emergency hotline or scheduled doctor appointments, would spare valuable ... Hospital in Boston, said in the report, recently published ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... this week expressed growing concerns over a rise in rates ... New data released Tuesday at the National HIV Prevention Conference ... that 19 percent of gay and bisexual men, 9 percent ...
... Reporter , TUESDAY, Aug. 16 (HealthDay News) -- Almost half ... and the risk of bladder cancer has increased significantly for ... Smokers now face a four times higher risk of ... years ago, that risk was about three times that of ...
... TUESDAY, Aug. 16 (HealthDay News) -- ,Scientists who identified ... a need for gender-specific drug therapies for some diseases. ... blood serum from more than 3,000 people and found ... in lipids and amino acids. The results prove ...
... , TUESDAY, Aug. 16 (HealthDay News) -- Black women ... are less likely to breast-feed, putting them at greater risk ... a new study. The study, published in the ... found the risk for hormone receptor-negative breast cancer was 50 ...
Cached Medicine News:Health News:Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines 2Health News:Sprained Ankles Straining ER Resources, Study Finds 2Health News:Experts Concerned About Rising HIV Rates Among Poor, Minorities 2Health News:Bladder Cancer Risk Even Higher for Smokers Than Thought 2Health News:Bladder Cancer Risk Even Higher for Smokers Than Thought 3Health News:Blacks at Higher Risk for Resistant Breast Cancer: Study 2
Inquire...
Inquire...
Nature's Remarkable Skin Protector -- Karaya 5 is a natural skin barrier that is particularly well suited for skin problems or for sensitive skin where reactions may have occurred to other types of s...
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Medicine Products: